Vericel Corporation – NASDAQ:VCEL
Vericel stock price today
$36.17
-21.15
-36.91%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 13 hours
Vericel stock price monthly change
+18.21%
month
Vericel stock price quarterly change
+18.21%
quarter
Vericel stock price yearly change
+62.04%
year
Vericel key metrics
Market Cap | 2.75B |
Enterprise value | 1.44B |
P/E | -85.36 |
EV/Sales | 8.80 |
EV/EBITDA | -124.38 |
Price/Sales | 8.83 |
Price/Book | 7.54 |
PEG ratio | 0.71 |
EPS | N/A |
Revenue | 207.77M |
EBITDA | 2.28M |
Income | 451K |
Revenue Q/Q | 25.02% |
Revenue Y/Y | 22.72% |
Profit margin | -10.17% |
Oper. margin | -10.38% |
Gross margin | 66.8% |
EBIT margin | -10.38% |
EBITDA margin | 1.1% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeVericel stock price history
Vericel stock forecast
Vericel financial statements
Average Price Target
$60.67
Potential upside: 67.72%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 45.92M | -5.02M | -10.93% |
|---|---|---|---|
| Sep 2023 | 45.58M | -3.66M | -8.03% |
| Dec 2023 | 64.99M | 12.99M | 19.99% |
| Mar 2024 | 51.28M | -3.86M | -7.53% |
| 2022-08-03 | -0.29591 | -0.19 |
|---|---|---|
| 2022-11-09 | -0.19215 | -0.14 |
| 2023-02-23 | -0.17143 | 0.12 |
| Jun 2023 | 310711000 | 111.78M | 35.98% |
|---|---|---|---|
| Sep 2023 | 318125000 | 113.74M | 35.75% |
| Dec 2023 | 353657000 | 127.70M | 36.11% |
| Mar 2024 | 356661000 | 122.76M | 34.42% |
| Jun 2023 | 10.19M | -2.40M | 1.19M |
|---|---|---|---|
| Sep 2023 | 7.16M | 4.56M | 1.00M |
| Dec 2023 | 10.08M | -8.08M | 1.30M |
| Mar 2024 | 7.20M | -25.45M | 2.12M |
Vericel alternative data
| Aug 2023 | 305 |
|---|---|
| Sep 2023 | 305 |
| Oct 2023 | 305 |
| Nov 2023 | 305 |
| Dec 2023 | 305 |
| Jan 2024 | 305 |
| Feb 2024 | 305 |
| Mar 2024 | 314 |
| Apr 2024 | 314 |
| May 2024 | 314 |
| Jun 2024 | 314 |
| Jul 2024 | 314 |
Vericel other data
63.43%
-36.57%
of VCEL is owned by hedge funds
137
-40
29.89M
-20.47M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 0 | 35652 |
| Feb 2024 | 0 | 722 |
| Mar 2024 | 0 | 55901 |
| Apr 2024 | 0 | 35000 |
| May 2024 | 0 | 45000 |
| Jun 2024 | 0 | 50000 |
| Jul 2024 | 0 | 55545 |
| Aug 2024 | 0 | 42000 |
| Sep 2024 | 0 | 55834 |
| Oct 2024 | 0 | 47234 |
| Nov 2024 | 0 | 49500 |
| Dec 2024 | 0 | 12600 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | WOTTON PAUL K director | Common Stock | 2,600 | $58.72 | $152,672 | ||
Option | HOPPER JONATHAN MARK officer: Chief Me.. | Common Stock | 10,000 | $16.66 | $166,600 | ||
Sale | HOPPER JONATHAN MARK officer: Chief Me.. | Common Stock | 10,000 | $58.72 | $587,200 | ||
Option | HOPPER JONATHAN MARK officer: Chief Me.. | Stock Option (Right to Buy) | 10,000 | $16.66 | $166,600 | ||
Option | ZERBE ROBERT L MD director | Common Stock | 2,500 | $13.05 | $32,625 | ||
Sale | ZERBE ROBERT L MD director | Common Stock | 2,500 | $60 | $150,000 | ||
Option | ZERBE ROBERT L MD director | Stock Option (Right to Buy) | 2,500 | $13.05 | $32,625 | ||
Option | COLANGELO DOMINICK director, officer.. | Common Stock | 17,500 | $3.02 | $52,850 | ||
Sale | COLANGELO DOMINICK director, officer.. | Common Stock | 17,500 | $53.93 | $943,775 | ||
Option | COLANGELO DOMINICK director, officer.. | Stock Option (Right to Buy) | 17,500 | $3.02 | $52,850 |
| Patent |
|---|
Application Filling date: 7 Dec 2018 Issue date: 25 Feb 2021 |
| Quarter | Transcript |
|---|---|
| Q1 2024 8 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 29 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 8 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 2 Aug 2023 | Q2 2023 Earnings Call Transcript |
Adoption Of Delcath's Hepzato Kit Will Snowball Quicker Than The Market Expects
AVITA Medical's 'Better Mousetrap' Rapidly Gaining Traction In Skin Repair
Vericel: Multiyear Growth Catalysts, Proprietary Solutions Will Drive Market Cap Expansion
Vericel Corporation: A Promising Future In Advanced Cell Therapies
Vericel: Aggressive Growth In 2023
Vericel: Poised For Growth
Vericel - A Disruptive Business With Years Of Growth Remaining
Vericel: In The Middle Of Difficulty Is An Opportunity
BioDelivery Sciences: Yet Another Buying Opportunity
-
What's the price of Vericel stock today?
One share of Vericel stock can currently be purchased for approximately $36.17.
-
When is Vericel's next earnings date?
Unfortunately, Vericel's (VCEL) next earnings date is currently unknown.
-
Does Vericel pay dividends?
No, Vericel does not pay dividends.
-
How much money does Vericel make?
Vericel has a market capitalization of 2.75B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 20.17% to 197.52M US dollars. Vericel made a loss 3.18M US dollars in net income (profit) last year or $0.12 on an earnings per share basis.
-
What is Vericel's stock symbol?
Vericel Corporation is traded on the NASDAQ under the ticker symbol "VCEL".
-
What is Vericel's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Vericel?
Shares of Vericel can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Vericel's key executives?
Vericel's management team includes the following people:
- Mr. Dominick C. Colangelo Esq. Chief Executive Officer, Pres & Director(age: 61, pay: $1,190,000)
- Mr. Michael Halpin Chief Operating Officer(age: 64, pay: $585,430)
- Dr. Jonathan M. Hopper Chief Medical Officer(age: 63, pay: $523,680)
- Mr. Sean C. Flynn Vice President, Gen. Counsel & Sec.(age: 51, pay: $502,690)
-
How many employees does Vericel have?
As Jul 2024, Vericel employs 314 workers.
-
When Vericel went public?
Vericel Corporation is publicly traded company for more then 28 years since IPO on 4 Feb 1997.
-
What is Vericel's official website?
The official website for Vericel is vcel.com.
-
Where are Vericel's headquarters?
Vericel is headquartered at 64 Sidney Street, Cambridge, MA.
-
How can i contact Vericel?
Vericel's mailing address is 64 Sidney Street, Cambridge, MA and company can be reached via phone at +61 75885555.
-
What is Vericel stock forecast & price target?
Based on 3 Wall Street analysts` predicted price targets for Vericel in the last 12 months, the avarage price target is $60.67. The average price target represents a 67.72% change from the last price of $36.17.
Vericel company profile:
Vericel Corporation
vcel.comExchange:
NASDAQ
Full time employees:
314
Industry:
Biotechnology
Sector:
Healthcare
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
64 Sidney Street
Cambridge, MA 02139
Cambridge, MA 02139
CIK: 0000887359
ISIN: US92346J1088
CUSIP: 92346J108
